Monte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancer

Reuters2026/08/06 11:23

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa Therapeutics completed enrollment and dosing in its GFORCE-1 Phase 1 study of MRT-8102 in people with elevated cardiovascular risk.
Results were previously presented in part, with additional findings scheduled for release in H2 2026.
Early readouts showed MRT-8102 reduced systemic inflammation, supporting broader development across sterile inflammation-driven diseases.
Multiple Phase 2 studies are slated to start from H2 2026, including a mid-stage trial in cardiometabolic and atherosclerotic risk.
Separately, a Phase 2a/b trial of VAV1-targeting MRT-6160 in Sjögren’s disease has been activated under Novartis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336681), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Monte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancer

You may also like

Crypto prices